Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.
Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD software to significantly improve the accuracy and speed of prostate cancer detection (CADe) and diagnosis (CADx).
News|Prostate Cancer
Bot Image Receives FDA Clearance for Artificial Intelligence Software Used in Detection and Diagnosis of Prostate Cancer

August 9, 2022 — Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD ...

TimeAugust 09, 2022
arrow
NorthStar will provide Clovis with its environmentally preferred, high purity non-carrier-added (n.c.a.) Ac-225
News|PET Imaging
Independent Clinical Studies Published Regarding Performance of Axumin (Fluciclovine F 18) PET Imaging in Patients with Recurrent Prostate Cancer Undergoing Androgen Deprivation Therapy (ADT)

July 20, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

TimeJuly 20, 2022
arrow
News|Prostate Cancer
Insightec Receives FDA IDE Approval for Prostate Cancer Comparative Study Using High Intensity Focused Ultrasound Technology

July 1, 2022 — Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care ...

TimeJuly 01, 2022
arrow
Heat maps of PSMA PET prostatic fossa recurrence in patients with recurrence limited to the prostate fossa (miTr N0 M0, n=127), pelvic nodal disease (miTr N1 M0, n=30), distant organs/extra-pelvic nodal disease (miTr N0 M1, n=32) and pelvic nodal plus distant organs/extra-pelvic nodal disease (miTr N1 M1, n=37). The yellow contour represents the RTOG CTV
News|Prostate Cancer
PSMA PET Highlights Need for Updated Prostate Cancer Therapy Guidelines

June 15, 2022 — Current guidelines used to plan salvage radiation treatments in patients with local recurrence of ...

TimeJune 15, 2022
arrow
At the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2022 Annual Meeting, GE Healthcare showcases cutting-edge solutions spanning the care continuum and enabling theranostics in prostate cancer
News|Prostate Cancer
GE Healthcare’s Total Molecular Imaging Solutions Enable Precision Health and Theranostics for Personalized Prostate Cancer Care

June 10, 2022 — GE Healthcare provides cutting-edge molecular imaging solutions that enable and increase access to ...

TimeJune 10, 2022
arrow
News|PET Imaging
Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

June 8, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

TimeJune 08, 2022
arrow
Craig Rogers, M.D., performed a robotic high intensity ultrasound case for Charles Rashid, 64, on April 8, 2022. Image courtesy of Henry Ford Health
News|Focused Ultrasound Therapy
Henry Ford Health First in Michigan to Offer Robotic High-intensity Focused Ultrasound for Prostate Cancer

May 12, 2022 — Henry Ford Health is the first in Michigan to offer Robotic High Intensity Focused Ultrasound (HIFU) for ...

TimeMay 12, 2022
arrow
Lumea, a global leader in integrated digital pathology solutions and Verily, an Alphabet precision health company, announced a strategic development partnership.
News|Digital Pathology
Verily and Lumea Announce Development Partnership

April 27, 2022 — Lumea, a global leader in integrated digital pathology solutions and Verily, an Alphabet precision ...

TimeApril 27, 2022
arrow
Over the past 15 years, public health authorities have downgraded recommendations for the prostate-specific antigen (PSA) test as a screening tool to reduce the overdiagnosis and overtreatment of men with low-grade prostate cancer.
News|Prostate Cancer
Less Prostate Cancer Screening Reduces Overdiagnosis but May Miss Aggressive Cases

April 25, 2022 — Over the past 15 years, public health authorities have downgraded recommendations for the prostate ...

TimeApril 25, 2022
arrow
Bracco公司Blue Earth Therapeutics是创新下一代放射性治疗药物研发领域的新兴领导者，该公司今天宣布，美国食品和药物管理局(FDA)批准了该公司177Lu-rhPSMA-10.1的试验性新药申请(IND)。
News|Prostate Cancer
Blue Earth Therapeutics Announces U.S. FDA Clearance for Investigational New Drug (IND) Application for 177Lu-rhPSMA-10.1

April 19, 2022 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

TimeApril 19, 2022
arrow
Prof. Dr. Samer Ezziddin, image courtesy of Thorsten Mohr/Saarland University
News|Prostate Cancer
New Radiotracer Yields Huge Increase in Accuracy of Localizing Prostate Cancer relapses

April 15, 2022 — Prostate cancer is the most common malignant tumor in men in Germany, with about 62,000 new cases ...

TimeApril 14, 2022
arrow
Quantitative analysis of pre-treatment PSMA PET/CT in a patient undergoing treatment with ¹⁷⁷Lutetium-PSMA-617/NOX66. Post-treatment PSMA PET/CT demonstrates reduced tumor volume and PSMA intensity. Images created by S Pathmanandavel and L Emmett, St Vincent's Hospital, Sydney, Australia.
News|PET-CT
New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients

2022年4月11日-一种新型核医学联合疗法已被证明对严重的前…

TimeApril 11, 2022
arrow
RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced artificial intelligence (AI) and computer vision solutions, announced a new tool for prostate MRI analysis.
News|Prostate Cancer
New AI Tool for Prostate MRI Analysis to Support PI-RADS Scoring

April 11, 2022 — RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced ...

TimeApril 11, 2022
arrow
《jnccn -国家综合癌症网络杂志》2022年3月号的研究分析了2016年9月25日至2020年9月26日安大略省癌症登记处的数据，以确定COVID-19大流行对检测到的新癌症病例数量的影响。
News|Coronavirus (COVID-19)
New Research in JNCCN Measures Drop in Cancer Detection Due to the COVID-19 Pandemic

April 6, 2022 — Research in the March 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined ...

TimeApril 06, 2022
arrow
周五，4月1日下午2点，西奈山的米尔顿和卡罗皮特里泌尿科将在东120街451号Wagner Houses的社区广场举行剪彩仪式，庆祝西奈山罗伯特F.史密斯移动前列腺癌筛查单元的成立。
News|Prostate Cancer
Mount Sinai Health System Launches First-Ever Mobile Prostate Cancer Screening Unit in New York City

2022年4月6日——4月1日下午2点，西奈山泌尿科的米尔顿和卡罗尔·皮特里将……

TimeApril 06, 2022
arrow
The American College of Radiology (ACR) has selected 22 teams as the first cohort of the ACR Learning Network, a new initiative to improve diagnostic imaging through a learning health system approach.
News|Radiology Education
New ACR Initiative Harnesses Learning Health System Approach to Improve Diagnostic Imaging

April 5, 2022 — The American College of Radiology (ACR) has selected 22 teams as the first cohort of the ACR Learning ...

TimeApril 05, 2022
arrow
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports Advanced Accelerator Applications, a Novartis company, as a long-term supplier for the medical radioisotope component of the newly U.S. Food and Drug Administration (FDA) approved radiotherapeutic, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treat
News|Prostate Cancer
ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

March 28, 2022 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports ...

TimeMarch 28, 2022
arrow
With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC)—the Society of Nuclear Medicine and Molecular Imaging (SNMMI) celebrates one of the greatest success stories in nuclear medicine history.
News|Prostate Cancer
SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical ...

TimeMarch 23, 2022
arrow
A new study from Keck Medicine of USC finds that the incidence rate of metastatic prostate cancer has significantly increased for men 45 and older and coincides with recommendations against routine prostate cancer screenings.
News|Prostate Cancer
Metastatic Prostate Cancer on the Rise Since Decrease in Cancer Screenings

March 23, 2022 — A new study from Keck Medicine of USC finds that the incidence rate of metastatic prostate cancer has ...

TimeMarch 23, 2022
arrow
Convergent will use NorthStar’s Ac-225 to radiolabel its lead asset, CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody, currently being investigated as a potential ground-breaking treatment for prostate cancer.
News|Prostate Cancer
NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

March 11, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

TimeMarch 11, 2022
arrow
© Copyright卡塔尔世界杯亚洲12强赛程. All Rights Reserved.
Subscribe Now